



Contact:

Dr. Misha Plam

President & CEO

T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

Dr. David L. Barker joins the Board of Directors of AmideBio, LLC

BOULDER, CO, August 17, 2011 – AmideBio, LLC, a privately held biopharmaceutical company which has developed novel manufacturing processes for peptides and proteins, has elected David. L. Barker, Ph.D., to its Board of Directors. In his role as director, Dr. Barker will help define the strategic goals of the company.

Dr. David L. Barker currently serves on the Boards of Directors of BioNanomatrix, Integrated Diagnostics, IntegenX Inc., ProteinSimple, and NextBio, and is a scientific advisor to Illumina, Diagnostics for the Real World, and BiOptix. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 through 2006. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.

In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

“We are very pleased to have Dr. Barker join our Board of Directors,” said Dr. Misha Plam, AmideBio President and CEO. “I’ve known David personally for many years and have a great respect for his integrity and experiences in helping startup companies become successful. He brings to the Company broad and in-depth scientific, business and corporate governance experience to the Board. His insights and experiences will prove vital to the Company as AmideBio moves to our next stage of growth and development in the Biosimilars market.”

“Improving the quality of therapeutic peptides and proteins, while reducing production costs, is a tremendous opportunity,” said David Barker. “I’m delighted to join AmideBio at this exciting period in its development.”

About AmideBio:

AmideBio, based in Boulder, CO, is a biotechnology company founded on a unique process for the production of peptides and proteins, especially those that have been historically difficult to manufacture or produce in large quantities. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at inflammatory and neurodegenerative diseases. The AmideBio

BioPure™ process is providing the research community with some of the most pure peptide-derived products available to date, including amyloid-beta, an important protein believed to be involved with Alzheimer disease. The Company's platform offers an economical and environmentally sustainable process for large-scale production of Biosimilars, with the aim of providing patients with lower-cost medications. AmideBio's technology is the foundation for internal drug discovery and development against diseases such as Diabetes and Alzheimer's, where our BioPure™ materials have allowed for the discovery of novel targets as well as potential improvements in existing therapeutics.

- ENDS